--- title: "Tivic Health Systems (TIVC) Stock Surges Over 24% After Hours: Here's What Is Happening" type: "News" locale: "en" url: "https://longbridge.com/en/news/283969568.md" description: "Tivic Health Systems Inc. (NASDAQ:TIVC) shares surged 24.10% to $1.39 after hours following the announcement of a rebrand to Valion Bio, Inc. and a strategic shift towards Entolimod-based immunotherapy. The company is exiting consumer medical devices and focusing on Entolimod™, which has received FDA Fast Track and Orphan Drug designations. Valion Bio is pursuing contracts with U.S. agencies for potential significant revenue. Despite the surge, the stock has dropped 84.09% over the past year and remains near its 52-week low." datetime: "2026-04-24T08:17:18.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/283969568.md) - [en](https://longbridge.com/en/news/283969568.md) - [zh-HK](https://longbridge.com/zh-HK/news/283969568.md) --- # Tivic Health Systems (TIVC) Stock Surges Over 24% After Hours: Here's What Is Happening **Tivic Health Systems Inc.** (NASDAQ:TIVC) shares jumped 24.10% to $1.39 in after-hours trading after the San Antonio-based company announced a full corporate rebrand to **Valion Bio, Inc.**, with its ticker shifting to VBIO at market open on April 28. ## Strategic Transformation Behind The Rebrand The rebrand caps a fundamental strategic pivot, exiting consumer medical devices and repositioning around Entolimod™, a TLR5 agonist developed as a medical countermeasure for acute radiation syndrome, with **Food and Drug Administration** Fast Track and Orphan Drug designations. The asset is advancing under the FDA’s Animal Rule pathway, which permits approval based on animal efficacy data when human trials are not feasible or ethical. Valion Bio is actively engaging the Biomedical Advanced Research and Development Authority (BARDA), the Defense Threat Reduction Agency (DTRA), and the National Institute of Allergy and Infectious Diseases (NIAID) regarding Entolimod’s inclusion in the U.S. Strategic National Stockpile— a procurement contract the company says could represent a non-dilutive, nine-figure revenue event. **Read Also: FreeCast Is Trending Overnight — Here's Why CAST Stock Surged Over 87% In The After-Hours Session** ## Trading Metrics, Technical Analysis Tivic Health, a late-stage immunotherapeutics company, has a market capitalization of $3.22 million, with a 52-week high of $7.74 and a 52-week low of $0.72. The Relative Strength Index (RSI) of TIVC stands at 56.26. The small-cap stock has dropped 84.09% over the past 12 months. Currently, the stock is positioned at about 5.7% above its 52-week low, meaning it is still trading near the lower end of its yearly range. **Price Action:** Tivic closed the regular session down 1.75% at $1.12, according to Benzinga Pro. **Benzinga's Edge Stock Rankings** indicate that TIVC is experiencing long-term consolidation along with medium and short-term upward movement. _Photo Courtesy: abunuh051992 on Shutterstock.com_ **Disclaimer:** This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors. **Read Also: IQSTEL (IQST) Stock Jumps 31% After Hours: Here's What You Should Know** ### Related Stocks - [TIVC.US](https://longbridge.com/en/quote/TIVC.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [VBIO.US](https://longbridge.com/en/quote/VBIO.US.md) - [CAST.US](https://longbridge.com/en/quote/CAST.US.md) - [IQST.US](https://longbridge.com/en/quote/IQST.US.md) - [IQSTD.US](https://longbridge.com/en/quote/IQSTD.US.md) ## Related News & Research - [Pulse Biosciences Reports Strong nPulse Atrial Fibrillation Data](https://longbridge.com/en/news/284232599.md) - [Canaccord Genuity Sticks to Their Buy Rating for Adicet Bio (ACET)](https://longbridge.com/en/news/283827775.md) - [Erasca Shares Phase 1 ERAS-0015 Data: 62% NSCLC Response, ctDNA Clearance Signals](https://longbridge.com/en/news/284275878.md) - [Medtronic PLC $MDT Shares Acquired by Kingswood Wealth Advisors LLC](https://longbridge.com/en/news/283974373.md) - [Tilray Brands Positioned for U.S. Expansion Amid Historic Cannabis Rescheduling | TLRY Stock News](https://longbridge.com/en/news/283837223.md)